曲安奈德联合阿柏西普治疗雷珠单抗应答不良的湿性年龄相关性黄斑变性

Triamcinolone Acetonide combined with Aflibercept in the treatment of wet age-related macular degeneration with poor response to Ranibizumab

摘要:

目的：比较阿柏西普玻璃体内注射联合曲安奈德后部眼球筋膜下注射治疗抗血管内皮生长因子(VEGF)药物雷珠单抗应答不良的湿性年龄相关性黄斑变性(ARMD)的效果及安全性。

方法：回顾性队列研究。2018-06/2020-05对抗VEGF药物雷珠单抗治疗应答不良的难治性ARMD 60例60眼，随机分为阿柏西普对照组及曲安奈德联合阿柏西普观察组，每组30例30眼。两组患者每月1次分别行单纯阿柏西普玻璃体内注射或阿柏西普玻璃内注射联合曲安奈德后部眼球筋膜下注射，连续注射3次。分别于注射前和注射第3次后1、3、6mo进行复查视力(BCVA)、黄斑中心凹厚度(CMT)及眼压的改变。

结果：两组患者在治疗后1、3、6mo的BCVA及CMT均明显好转(P<0.05)。观察组治疗后1mo平均眼压较前升高，但仍在正常范围，两组眼压比较有差异(17.50±4.60 vs 18.30±3.73mmHg，P<0.05)。

结论：曲安奈德后部眼球筋膜下注射联合阿柏西普玻璃体内注射治疗湿性ARMD，有效地减轻黄斑区水肿并改善视力，更加安全可靠。

Abstract:

AIM: To compare the efficacy and safety of intravitreal injection of aflibercept combined with posterior sub-fascial injection of triamcinolone acetonide in the treatment of wet age-related macular degeneration(ARMD)with poor response to anti-vascular endothelial growth factor drugs.

METHODS: Retrospective cohort study. From June 2018 to May 2020, a total of 60 patients(60 eyes)with refractory ARMD who had poor response to the treatment of anti VEGF drug ranibizumab were randomly divided into the control group of aflibercept and the observation group of triamcinolone acetonide combined with aflibercept, with 30 patients(30 eyes)in each group. Once a month, the patients in the two groups received intravitreal injection of aflibercept alone or intravitreal injection of aflibercept combined with posterior sub-fascial injection of triamcinolone acetonide for three consecutive times. The changes of best corrected visual acuity(BCVA), central macular thickness(CMT)and intraocular pressure were reviewed before injection and 1, 3 and 6mo after the third injection.

RESULTS: The BCVA and CMT of the two groups were significantly improved 1, 3 and 6mo after the injection of the drug(P<0.05). The mean intraocular pressure in the combined group was higher at 1mo after treatment than before, but it still within the normal range. There was a significant difference in intraocular pressure between the two groups(17.50±4.60 vs. 18.30±3.73mmHg, P<0.05).

CONCLUSION: Triamcinolone acetonide injection under the posterior fascia of the eyeball combined with intravitreal injection of aflibercept in the treatment of wet ARMD can effectively reduce macular edema and improve vision, which is more safe and reliable.